[ad_1]
Production and transportation of Corona 19 (PG) vaccine▶ Click here to enlarge the view
The government has decided to introduce a new vaccine against the infectious disease coronavirus (Corona 19) that is being developed abroad, and it is noted that negotiations are underway with the relevant pharmaceutical companies to accelerate the time of introduction.
Yang Dong-gyo, director of the Korea Centers for Disease Control and Prevention, said in a regular briefing on the 24th, explaining the status of the vaccine purchase contract with Johnson & Johnson-Jansen and Pfizer.
Prime Minister Jeong Sye-gyun announced that he had signed a vaccine purchase contract with Pfizer for 10 million people (20 million doses) and Johnson & Johnson-Jansen at the morning’s Disaster Countermeasures Headquarters meeting. for 6 million people.
Of the government’s initial target of 44 million people, contracts were completed for a total of 26 million people, including AstraZeneca’s 10 million people (20 million lots). 4 million people were planned to be insured through Janssen, but 2 million people were added in the actual contract process.
The government plans to insure an additional 10 million people, a total of 20 million people, through the ‘COVAX facility’, an international project for the joint purchase and distribution of Monna and vaccines. He is negotiating with Modena with the goal of a contract in January.
Regarding the timing of the introduction of these vaccines in Korea, the two directors said: “The timing of the vaccine supply varies depending on the pharmaceutical company, the production volume and the timing of the contract.” Will be presented “.
Yang Dong-gyo, Director, Office of Medical Safety Prevention, Korea Centers for Disease Control and Prevention, briefing▶ Click here to enlarge the view
In particular, he emphasized, “Even after signing the contract, we are trying to pull the (introductory) period in various ways” and “I am continually arguing with pharmaceutical companies in that direction.”
However, he said, “The specific introduction schedule will be decided in detail taking into account the national vaccination plan, etc.,” he said. “There is a confidentiality agreement when contracting with the manufacturer, so the detailed delivery time and the quantity indicated in the contract cannot be disclosed.”
Director Yang said, “We are establishing an inoculation plan taking into account the timing of supply and the characteristics and efficacy of vaccines by manufacturer, and vaccination is recommended for those for whom priority vaccination is recommended before November and December. next year. The goal, ”he said.
Regarding this, Ko Jae-young, spokesperson for the Korea Centers for Disease Control and Prevention, said: “I will briefly summarize the specific implementation plans and explain them at the regular briefing next Monday (28)” .
Director Yang dismissed the observation that there is the possibility of production of domestic shipments with the fact that the volume of the contract with Janssen increased by 2 million more than originally expected, saying: “The possibility of production of shipments has not been discussed. “. “We work hard, and thanks to the cooperation of the manufacturer, we have signed 2 million more times.”
Director Yang also responded, “We confirmed that there is no effect on the vaccines to be supplied to Korea,” when asked if it would be difficult to secure domestic supplies, as the US decided to purchase additional Pfizer vaccines by mobilizing the defense material production method.
He said: “I was initially told to provide specific information by the end of December. We will provide information to participating countries soon.”
Meanwhile, it is known that each pharmaceutical company continues to demand “ immunity to side effects ” from each country as they quickly manufactured the vaccine.
Director Yang said: “According to the manufacturers of Corona 19, contract-related disclaimers are inevitably accepted to some extent in each country and are commonly applied around the world,” which implies that they have accepted them.
“The development of the Corona 19 vaccine is unprecedented, and competition is fierce globally to secure the vaccine,” he said. “In such a special situation, it is difficult to assume the usual responsibility of the manufacturer. “I have.”
[연합뉴스]
Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
